A Phase II Study of N-acetylcysteine in Patients with COVID-19 Infection

Share
Print

Full Title

Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients with Refractory COVID-19 Infection (COVID)

Purpose

The purpose of this study is to see if the drug N-acetylcysteine is effective for treating people with severe COVID-19 infection who are in an intensive care unit (ICU) and/or on a ventilator and in those who are not in an ICU but need extra oxygen to breathe. Doctors hope that N-acetylcysteine could help patients leave the ICU, be taken off a ventilator, or be spared from ventilator support and care in an ICU.

Researchers think that N-acetylcysteine could increase the number of white blood cells called lymphocytes in patients with COVID-19 and help them fight the infection. The drug is also used to help loosen mucus in the lungs of people with cystic fibrosis and chronic obstructive lung disease. The use of N-acetylcysteine in this study is considered investigational. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be hospitalized with severe COVID-19 infection.
  • Patients must be in an intensive care unit (ICU) and/or on a ventilator, or not in an ICU but receiving extra oxygen to breathe.
  • This study is for patients age 18 and older.

For more information about this study, please contact Dr. Santosha Vardhana at 646-888-3285.

Protocol

20-168

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators